Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CANOPY-1
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 11 Feb 2024 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 27 Dec 2023 Planned End Date changed from 23 Jul 2024 to 7 Jun 2027.
- 01 Dec 2023 Results assessing the addition of canakinumab to first-line pembrolizumab and chemotherapy in patients with non-small-cell lung cancer published in the Journal of Clinical Oncology